A randomized controlled trial comparing zileuton with theophylline in moderate asthma

Archives of Internal Medicine

Volumn 158, Issue 2, 1998, Pages 141-148

  Schwartz, Howard J ^a,d   Petty, Thomas ^b   Dubé, Louise M ^c   Swanson, Linda J ^c   Lancaster, James F ^c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b PRESBYTERIAN ST LUKE S MEDICAL CENTER   (United States)

^c ABBOTT LABORATORIES   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PLACEBO; SALBUTAMOL; THEOPHYLLINE; ZILEUTON;

ADULT; ARTICLE; ASTHMA; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INSOMNIA; LIVER TOXICITY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; ASTHMA; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYDROXYUREA; LIPOXYGENASE INHIBITORS; LUNG VOLUME MEASUREMENTS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THEOPHYLLINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031964913     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.2.141     Document Type: Article

References (15)

1. Weinberger MM. Methylxanthines in Bronchial Asthma: Mechanisms and Therapeutics. 3rd ed. Boston, Mass: Little Brown & Co; 1993:764-783.
2. Nicklas R, Yanowitz E. Asthma. In: Spagnolo SV, Nicklas RA, Witorsch P, eds. Handbook of Pulmonary Drug Therapy. Boston, Mass: Little Brown & Co; 1994:1-33.
3. Weiss JN, Drazen JM, Coles N. Bronchoconstrictor effects of leukotriene C in humans. Science. 1982;216:196-198.
4. Barnes NC, Piper PJ, Costello JF. Comparative effects of inhaled leukotriene C4, leukotriene D4 and histamine in normal subjects. Thorax. 1984;39:500-504.
5. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med. 1990;323:645-655.
6. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med. 1990;323:1740-1744.
7. Israel E, Rubin D, Kemp J, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med. 1993;119:1059-1066.
8. Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76-83.
9. Arky R. Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics Co; 1996:2033-2036.
10. Horn BR, Robin ED, Theodore J, Van Kessel A. Total eosinophil counts in the management of bronchial asthma. N Engl J Med. 1975;292:1152.
11. Schwartz HJ, Lowell FC, Melby JC. Steroid resistance in bronchial asthma. Ann Intern Med. 1968;69:493-499.
12. Venge P, Dahl R, Peterson CG. Eosinophil granule proteins in serum after allergen challenge of asthmatic patients and the effects of anti-asthma medication. Int Arch Allergy Appl Immunol. 1988;87:306-312.
13. Griffin E, Hakansson L, Formgren H, Jorgensen K, Peterson C, Venge P. Blood eosinophil number and activity in relation to lung function in patients with asthma and with eosinophilia. J Allergy Clin Immunol. 1991;87:548-557.
14. Janson C, Herald M. Blood eosinophil count as risk factor for relapse in acute asthma. Respir Med. 1992;86:101-104.
15. Israel E, Conn J, Dubé L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA. 1996;275:931-936.